ANSTO's Lucas Heights Precinct in Sydney is home to three key facilities that enable Australia's advanced manufacturing and distribution of nuclear medicines.
Nuclear medicine and your health
Every Australian is likely to benefit from nuclear medicine and on average will have at least two nuclear medicine procedures in their lifetime.Learn about nuclear medicine and your health
Take a look at how Molybdenum-99 (Mo-99), the most widely used nuclear medicine in the world, is manufactured at ANSTO.
Mo-99 is produced in the ANSTO's OPAL nuclear reactor, processed at the Mo-99 Manufacturing Facility and despatched to practitioners in shielded Gentech® Generators.See video
On average, ANSTO’s radioisotopes provide 10,000-12,000 nuclear medicine procedures that benefit Australians each week.
Lutetium-177: Prostate cancer and melanoma
ANSTO is the supplier of non-carrier added (n.c.a) Lutetium-177 (Lu-177) used in prostate cancer and melanoma clinical trials being undertaken by ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre and Melanoma & Skin Cancer Trials.
Follow the journey
Every Australian is likely to benefit from nuclear medicine and, on average, will have at least two nuclear medicine procedures in their lifetime.
See how nuclear medicine makes its way from ANSTO's OPAL reactor to medical centres around Australia.View video
News & Innovation
ANSTO researchers are continuously working to develop new nuclear medicines to help fight diseases, including cancer, by using our comprehensive science kit and radiochemicals.
 based on published Medicare statistics combined with non-MBS data sourced from the nuclear medicine community: http://medicarestatistics.humanservices.gov.au/statistics/mbs_group.jsp.
 These include diagnostic imaging scans (SPECT and PET) to aid in patient management and a growing range of therapies.